Kiniciti

Bringing novel treatments to the patients who need them most — in an economically viable way — is too often crippled by persistent bottlenecks, constraints, and inefficiencies in the development, manufacturing, and delivery of those innovations. At Kiniciti, our imperative is to make the promise of breakthrough CGT therapies a reality, so that future treatments reach patients as quickly and cost-efficiently as possible. There can’t be a tradeoff between scientific advancements and patients’ access to life-changing therapies; both must be addressed simultaneously. Kiniciti is focused on investing in opportunities with the potential to leverage technology and capabilities that can help drive transformational change and ensure the promise of CGT therapeutics is delivered to patients in need. Kiniciti is a new Welsh, Carson, Anderson & Stowe platform established to partner with companies that have the potential to transform the cell and gene therapy ecosystem and deliver the promise of these therapies to impact patients’ lives.